Question 1

What is Edwards Lifesciences's P/E ratio?

Accepted Answer

Edwards Lifesciences (EW) P/E ratio is 44.8× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Edwards Lifesciences?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Edwards Lifesciences specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Edwards Lifesciences's P/E ratio high or low?

Accepted Answer

Edwards Lifesciences's P/E ratio of 44.8× is above its own 5-year average of 33.8× and above the sector median of 24.2×. That places the current reading at the 80th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Edwards Lifesciences's historical P/E ratio range?

Accepted Answer

In the available daily series, Edwards Lifesciences (EW) P/E ratio has ranged from a low of 9.5× in 2024 to a high of 1446.6× in 2004. The 5-year average is 33.8× and the 5-year median is 36.0×.

Question 7

What was Edwards Lifesciences's P/E ratio in 2025?

Accepted Answer

Edwards Lifesciences (EW) P/E ratio at the end of 2025 was 46.2×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Edwards Lifesciences's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$49.5B	$1.07B	46.2×	+35.8×	Dec 31, 2025
2024	$43.7B	$4.17B	10.5×	-22.4×	Dec 31, 2024
2023	$46.1B	$1.4B	32.9×	+2.9×	Dec 31, 2023
2022	$45.7B	$1.52B	30.0×	-23.7×	Dec 31, 2022
2021	$80.9B	$1.5B	53.8×	-15.3×	Dec 31, 2021
2020	$56.9B	$823M	69.1×	+22.6×	Dec 31, 2020
2019	$48.7B	$1.05B	46.5×	+2.4×	Dec 31, 2019
2018	$31.9B	$722M	44.1×	+5.9×	Dec 31, 2018
2017	$23.8B	$622M	38.2×	+3.0×	Dec 31, 2017
2016	$20B	$570M	35.2×	+0.7×	Dec 31, 2016
2015	$17B	$495M	34.4×	+17.6×	Dec 31, 2015
2014	$13.7B	$811M	16.9×	-1.6×	Dec 31, 2014
2013	$7.18B	$390M	18.4×	-16.9×	Dec 31, 2013
2012	$10.4B	$293M	35.4×	+1.3×	Dec 31, 2012
2011	$8.07B	$237M	34.1×	-8.0×	Dec 31, 2011
2010	$9.18B	$218M	42.1×	+20.7×	Dec 31, 2010
2009	$4.9B	$229M	21.4×	-2.4×	Dec 31, 2009
2008	$3.07B	$129M	23.8×	+0.7×	Dec 31, 2008
2007	$2.61B	$113M	23.1×	+2.3×	Dec 31, 2007
2006	$2.71B	$131M	20.7×	-10.5×	Dec 31, 2006
2005	$2.48B	$79.3M	31.3×	-1415.3×	Dec 31, 2005
2004	$2.46B	$1.7M	1446.6×	+1424.1×	Dec 31, 2004
2003	$1.78B	$79M	22.5×	-4.3×	Dec 31, 2003
2002	$1.5B	$55.7M	26.8×	—	Dec 31, 2002


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Edwards Lifesciences (EW) 2002-2026

P/E Ratio daily chart for Edwards Lifesciences (EW)

Historical P/E Ratio for Edwards Lifesciences (EW) from 2002 to 2025

About P/E Ratio at Edwards Lifesciences (EW)

Edwards Lifesciences P/E Ratio by Year

Edwards Lifesciences P/E Ratio 2025: 46.2×

Edwards Lifesciences P/E Ratio 2024: 10.5×

Edwards Lifesciences P/E Ratio 2023: 32.9×

Edwards Lifesciences P/E Ratio 2022: 30.0×

Edwards Lifesciences P/E Ratio 2021: 53.8×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Edwards Lifesciences (EW) Key Financials